Regenacy Pharmaceuticals received $30 million to help advance its lead candidate ricolinostat into Phase 2 studies for Charcot-Marie-Tooth (CMT) disease type 2, as well as diabetic and chemotherapy-induced peripheral neuropathy. The money comes from a series A financing round, which startup companies need to raise capital. The funding was co-led by Cobro Ventures and Taiwania … Continue reading With $30M Investment, Regenacy Plans Phase 2 Trial Testing Ricolinostat for CMT Type 2